Mirum posted Q2 2026 net product sales of USD 176.2 million, up from USD 127.8 million a year earlier.
Net loss widened to USD 67.23 million, or USD 1.06 per share, from a net loss of USD 5.86 million, or USD 0.12 per share.
Operating loss expanded to USD 42.54 million from USD 4.99 million as operating expenses climbed to USD 218.78 million from USD 132.77 million.
Mirum raised 2026 net product sales guidance to USD 680 million-USD 700 million; Q2 LIVMARLI sales rose 46% to USD 128.7 million.
Volixibat won FDA Breakthrough Therapy and Orphan Drug designations in PSC; NDA submission is now targeted for H1 2027, and zilurgisertib PDUFA is set for Sept. 26, 2026.
MIRM•
